共 42 条
- [1] RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROLJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1867 - 1867Cannon, Christopher P.Ginsberg, HenryRay, KausikDavidson, MichaelPordy, RobertBessac, LaurenceMinini, PascalEckel, Robert
- [2] Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibeFRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9Cheng, YinchuDong, ShujieShen, PengSun, YexiangLin, HongboZhai, Suodi
- [3] Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab TrialsCardiovascular Drugs and Therapy, 2018, 32 : 175 - 180Harold E. BaysRobert S. RosensonMarie T. Baccara-DinetMichael J. LouieDesmond ThompsonG. Kees Hovingh
- [4] MODELLING THE US POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROLJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 66 - 66Sanchez, RobertNasir, KhurramKlimchak, AlexaKuznik, AndreasJoulain, FlorenceBriggs, Andrew
- [5] Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab TrialsCARDIOVASCULAR DRUGS AND THERAPY, 2018, 32 (02) : 175 - 180Bays, Harold E.Rosenson, Robert S.Baccara-Dinet, Marie T.Louie, Michael J.Thompson, DesmondHovingh, G. Kees
- [6] Validity of a Novel Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Cardiovascular Disease Patients Treated with StatinsJOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (07) : 643 - 652Sonoda, TakeshiTakumi, TakuroMiyata, MasaakiKanda, DaisukeKosedo, IppeiYoshino, SatoshiOhishi, Mitsuru
- [7] Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsJOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (18):Vallejo-Vaz, Antonio J.Ginsberg, Henry N.Davidson, Michael H.Eckel, Robert H.Cannon, Christopher P.Lee, L. VeronicaBessac, LaurencePordy, RobertLetierce, AlexiaRay, Kausik K.
- [8] The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With PravastatinINTERNATIONAL HEART JOURNAL, 2014, 55 (01) : 39 - 47Daida, HiroyukiTeramoto, TamioKitagawa, YasuhisaMatsushita, YasuyukiSugihara, Masahiro
- [9] Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular DiseaseAMERICAN JOURNAL OF CARDIOLOGY, 2019, 123 (11): : 1739 - 1744Chamberlain, Alanna M.Cohen, Sarah S.Weston, Susan A.Fox, Kathleen M.Xiang, PinKillian, Jill M.Qian, Yi
- [10] Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlATHEROSCLEROSIS, 2019, 288 : 85 - 93Vallejo-Vaz, Antonio J.Ray, Kausik K.Ginsberg, Henry N.Davidson, Michael H.Eckel, Robert H.Lee, L. VeronicaBessac, LaurencePordy, RobertLetierce, AlexiaCannon, Christopher P.